Among different lymphoid neoplasms, CLL and DLBCL showed the most prominent upregulation of MSI2. Accordingly, MSI2 has been the focus of a comprehensive investigation in CLL demonstrating its involvement in tumorigenicity and its association with reduced OS (Palacios et al., 2021). Here, MSI2 is linked to diffuse large B-cell lymphoma.